The recombinant growth factors (GFs) erythropoietin (Epo) and granulocyte-macrophage colony stimulating factor (GM-CSF) have important roles in the management of cancer patients. However, the effects of these GFs at a cellular level are not well understood. We examined the effect of GFs alone, and in combination with cytotoxic chemotherapy, in a panel of seven cell lines. Flow cytometric analysis showed varying levels of receptor expression, which correlated with phosphorylated MAPK expression. Additionally, there were also concomitant increases in BCL-2 protein levels in those cells with high levels of MAPK activation. Although culturing cells with Epo or GM-CSF did not alter cell viability by themselves, GF pretreatment in cell lines expressing higher receptor levels resulted in a reduced magnitude of cell kill following exposure to cytotoxic IC 50 concentrations of cisplatin. Subsequent co-culture with either the MEK inhibitor U0126 or the GM-CSF antagonist E21R negated this induced resistance to cytotoxic chemotherapy, confirming the importance of the GF receptor as well as MAPK in mediating these effects. These results suggest that the use of GFs during chemotherapy may be detrimental in those cancers expressing higher levels of the specific receptor. Conversely, our results also suggest that GFs are safe to use in chemotherapeutic regimens if the cancer cells do not overexpress the particular receptor.
Introduction
The development of haemopoietic progenitor stem cells requires specific growth signals to ensure proper proliferation and differentiation. These growth factors (GFs), of which the colony stimulating factors (CSFs) and interleukins are the major protagonists, play important roles in maintaining cell viability (Williams et al., 1990) and controlling cellular differentiation towards distinct lineages (Sachs, 1996) . There is a complex interplay between these primary GFs, such as the granulocyte-macrophage CSF (GM-CSF), and secondary GFs, such as erythropoietin (Epo) (Sachs, 1996) , which together direct the process of growth from early stem cells through to mature granulocytes, macrophages and erythrocytes (Lopez et al., 1986) . These GFs have distinct roles. GM-CSF chiefly promotes cell survival by suppressing apoptosis via pathways that modulate members of the BCL-2 family (Bradbury et al., 1994; del Peso et al., 1997) , whereas Epo functions more as a differentiative agent, only having a minimal role in mediating cell death (Abels, 1993) .
Haemopoietic GFs such as GM-CSF and Epo are widely used in the clinical setting. Since the 1970s, GM-CSF has been used extensively in autologous and allogeneic bone transplantation (McCredie et al., 1970; Chervenick and Boggs, 1971; Clarke and Housman, 1977; Dempke et al., 2000) . However, more recently, it has been used in the treatment of a wide range of malignancies, allowing the dose of chemotherapy to be intensified as well as reducing the length of treatment-related neutropenia (Orazi et al., 1992; Laughlin et al., 1993) . Whether these particular CSFs result in a survival benefit in this setting remains unclear. Similarly, recombinant Epo (rhEpo) is also used to reduce the requirement for blood transfusions during chemotherapy (Clark et al., 2002; Vansteenkiste et al., 2002) , and has been shown to confer quality of life benefit in that setting (Fallowfield et al, 2002) .
Both GM-CSF and Epo have also been specifically used as antitumour agents with varying degrees of success. In vivo studies have shown GM-CSF to have potent antitumour effects via immune stimulation (Galea and Cogne, 2002) . However, there are also conflicting data implicating GM-CSF in the progression of a number of malignancies (Berdel et al., 1989; Everson et al., 1989; Ramshaw et al., 2002) . The specific role of GM-CSF and the GM-CSF-R in mediating these effects was confirmed by a series of studies from Angel Lopez's laboratory, showing that culture with the specific GM-CSF antagonist E21R resulted in apoptosis in haemopoietic cells (Iversen et al., 1996a (Iversen et al., , b, 1997 . Indeed, the later findings concluded that the GM-CSF-R might actually maintain the survival of cells by regulating their death via the ERK-MAPK pathways and BCL-2 family members (Lee and Mccubrey, 2002) . Unlike GM-CSF, there is no clear evidence that Epo mediates cell survival by suppressing apoptosis, and may involve additional signal transduction pathways other than MAPK (Garrington and Johnson, 1999) . The Epo-R has been isolated in both renal cancer and other solid tumours, and is thought to play a role in disease progression (Da Silva et al., 1990; Acs et al., 2002) . Similarly, in vitro studies have revealed conflicting results highlighting Epo to be both cytotoxic and proliferative in nature (Westenfelder and Baranowski, 2000; Westphal et al., 2002) .
With the increased use of dose-intensive chemotherapy, the clinical use of haemopoietic GFs to minimize chemotherapy-induced myelosuppression has become more widespread. However, many reports, notably that of Lotem and Sachs (1995) , have shown that GM-CSF could inhibit apoptosis induced by a range of chemotherapeutic agents. They concluded that the addition of GFs induced the expression of several transcription factors that paradoxically played an antiapoptotic role (Shabo et al., 1990) and, therefore, the administration of GF should be controlled to prevent any protection of malignant cells from the cytotoxic action of the chemotherapeutic agent.
This study attempts to address the conflicting issues surrounding the effects of GFs on cellular proliferation. The direct correlation between receptor levels and cellular function has yet to be elucidated. Therefore, by using a novel nonradioactive assay to analyse receptor levels, this study will specifically examine the relationship between GF-receptor stimulation and activation of complex downstream biochemical pathways that regulate cell proliferation and death. It will also address the effects of these GFs on the subsequent activity of cytotoxic chemotherapy.
Results

GFs do not increase the rate of proliferation
Cells cultured with GFs showed no significant changes in cell viability (%V in any GF-treated cell was always 77.3% of the respective control cells), in cell number ( Figure 1a ) and in the rate of cell proliferation (Figure 1b) . Flow cytometric analysis revealed no significant alterations to the cell cycle distribution in these cells cultured with either Epo or GM-CSF (Figure 2 ).
Receptor levels vary in each cell line
The levels of Epo-R and GM-CSF-R were assessed by a novel nonradioactive method, and the results indicated clear differences in their levels in the cell lines tested. As an example, Epo-R levels were variable, typically absent in CEM cells (3.470.7), but comparatively high in K562 cells (161.775.9) . In contrast, GM-CSF-R levels were highest in CEM cells (114.777.7) and lowest in Caki 1 cells (2.871.0) (Figure 3 ). 
Effect of GFs on MAPK activation
To investigate whether receptor levels correlated with activation of signal transduction pathways, whole-cell lysates from cells treated with Epo or GM-CSF for 3 days were separated by electrophoresis and immunoprobed for activated MAPK. Activated (di-phosphorylated) MAPK was seen in all samples, even in untreated cells, and was present in differing quantities according to the GF used (Figure 4) . Notably, the largest increases in MAPK activation was observed in CEM and HL60 cultured with GM-CSF and in K562 cells with Epo.
GM-CSF increases BCL-2 expression in CEM and HL60 cells
The levels of BCL-2 protein expression following a 3-day culture with Epo and GM-CSF were assessed by flow cytometry. Generally, Epo had no effect on BCL-2 expression; however, GM-CSF significantly increased BCL-2 levels in CEM and HL60 cells (71.775.7 and 6.370.2 vs 46.273.2 and 3.370 .1, respectively, in control cells with no GM-CSF; both Po0.001) ( Figure 5 ). Cisplatin-induced cytotoxicity is reduced in CEM and HL60 cells precultured with GM-CSF Cells were precultured with either Epo or GM-CSF for 3 days prior to induction of cell kill by culturing with an IC 50 concentration of cisplatin. As expected, culturing cells with an approximate IC 50 concentration of cisplatin resulted in a reduction in cell viability by about 50%. The only exception was in K562 cells, which have been previously shown to be characteristically resistant to most chemotherapeutic agents. The preculture of cells with Epo or GM-CSF typically did not cause any significant change in the sensitivity to subsequent exposure to cisplatin (Table 1 ). However, the most notable exceptions to this were CEM and HL60 cells pretreated with GM-CSF (which expressed the highest levels of GM-CSF-R), where the extent of cisplatininduced cell kill was significantly lower in cells precultured with GM-CSF (%V: 77.372.3 and 77.471.9 vs 51.073.5 and 50.071.0%, respectively, in control cells without GM-CSF; Po0.001) ( Figure 6 ). Flow cytometric analyses confirmed this reduction in cytotoxicity in CEM and HL60 cells by revealing a clear reduction in the extent of apoptosis in these cells pretreated with GM-CSF but not with Epo ( Figure 7 ). Effect of GFs on cisplatin-induced cell kill. Cells were precultured with Epo (10 IU/ml) or GM-CSF (100 ng/ml) for 3 days, before reculturing in IC 50 concentrations of cisplatin. Cell counts were performed on day 6. Data are expressed relative to control cells with no pretreatment, and represent the means and s.d.s of at least three separate experiments 
Reduction in cisplatin-induced cytotoxicity is dependent on MAPK activation
The importance of activated MAPK in determining the cellular response to GM-CSF and cisplatin was investigated in two ways. Firstly, we inhibited the upstream regulating MAPK kinase MEK with U0126. Immunoblot analyses showed a reduction in di-phosphorylated MAPK in CEM cells cultured with U0126 ( Figure 8a ). The results also indicated that a 3-day culture with single agent U0126 had no significant effect on cell viability (94.071.9 vs 95.671.3% in control cells). In contrast, the inhibitor significantly inhibited cell growth (cell number: 10.070.7 Â 10 5 /ml vs 14.870.9 Â 10 5 /ml; Po0.001) (Figure 8b ). U0126 had no significant effect on BCL-2 expression. However, the results showed that the GM-CSF-induced increase in the level of BCL-2 protein expression was completely abrogated by coculture with U0126 ( Figure 8b ). Subsequent cytotoxicity assays performed on these cells showed a reversal of the cisplatin resistance caused by culturing with GM-CSF alone, as a comparable loss of viability between these cells and control cells without GM-CSF pretreatment was observed (Figure 8c 
. Pretreating these cells with GM-CSF (100 ng/ml) for 3 days prior to culturing with cisplatin (IC 50 : 10 mM) resulted in slight increases in BCL-2 protein and decreases in sensitivity to cisplatin. However, these changes were not of the same magnitude as seen in the parental cell line cultured with the same agents (Figure 9d ).
Reduction in cisplatin-induced cytotoxicity is dependent on GM-CSF receptor binding
The importance of the GM-CSF-R in determining drug efficacy was investigated by culturing CEM cells with GM-CSF in the presence of the selective GM-CSF antagonist E21R. A concentration of 125 mg/ml of E21R was used in our experiments, as established by our binding studies (Figure 10a ). Culturing cells with E21R alone for 3 days had no significant effect on cell number and viability at concentrations up to 1 mg/ml (cell number and %V: 43.477.7 Â 10 5 cells/ml and 96.270.9% vs 52.078.4 Â 10 5 cells/ml and 97.070.8% in control cells with drug, respectively). However, coculturing GM-CSF with E21R reversed the GF-induced upregulation of Bcl-2 expression, and negated its antiapoptotic effects (Figure 10b and c) .
Discussion
This study was undertaken to investigate the effect of common GFs in a panel of cell lines, with specific CEM cells were precultured with GM-CSF, U0126 (MEK inhibitor), or a combination of the two (comb.). The extent of activated MAPK was then assessed by immunoblotting (a). Cell number and bcl-2 levels were also measured (b). Pretreated CEM cells were then cultured with 10 mM cisplatin (IC 50 ) and cell viability assessed after a 3-day treatment (c). Data points in graphs represent the means and s.d.s of at least three separate experiments interest in examining the relationship between GFreceptor expression and activation of biochemical pathways regulating cell kill. Particularly, the effect of GF on chemotherapy-induced cell kill was studied. We confirmed that GFs had no significant effect on cell growth and number, and that their use alone was not associated with increased cytotoxicity. The most significant finding of this study was that in cells highly expressive of GF receptor, culture with the respective GF could change BCL-2 expression. This resulted in an altered phenotype that was resistant to cisplatin-induced cell kill. Supplementary to this, the crucial role of the GF receptor in mediating this antiapoptotoic effect was confirmed using selective antagonists to the receptors.
In the first part of this investigation, we showed that both Epo and GM-CSF were neither cytotoxic nor cytostatic in quality, having no apparent effect on cell viability or on the rate of cell proliferation. It is important to stress that the cell lines were growing exponentially, were nonconfluent, and that the GFs were used at concentrations that were clinically applicable to patients (Kurzrock et al., 1991; Steward, 1993) .
It was important for us to ascertain the relative number of GF receptors in our panel of cell lines to establish if there was correlation between receptor levels and GF effect. Consequently, we next assessed the levels of Epo-R and GM-CSF-R by using a novel nonradioactive method involving the use of common biotin/ avidin associations (Bratthauer, 1999) . However, our method varied from these standard methods by employing extended ester linkages, which reduced the steric hindrance conferred by the bulky FITC-fluorochrome (de Jong et al., 1997) , and should result in a high degree of specificity. Additionally, using biotinylated whole ligands, rather than monoclonal antibodies, ensured that only structurally competent receptors were measured. Methodologically, receptor levels were expressed relative to the autofluorescence controls (the ratio of fluorescence in tested samples to the nude sample), and our results demonstrated the ease and sensitivity of this novel two-step method, and revealed clear differences in both Epo-R and GM-CSF-R levels in the cell lines tested. In particular, the myeloid CEM, HL60 and K562 cells displayed the highest levels of GM-CSF-R, which was unsurprising as these cells were derived from diseases at the later stages of haemopoiesis, which are dependent on GM-CSF for maturation. Additionally, our findings showed that renal lines expressed the , with GM-CSF resulted in increases in BCL-2 expression (white columns). However, this increase was significantly less than that seen in the parental cell cultured with GF. Also, the reduction in sensitivity to cisplatin seen in the parent was not as marked in HL60 -MEK cells (grey columns). Data points represent the means and s.d.s of at least three separate experiments Figure 10 Effect of the GM-CSF antagonism on GF-induced resistance. CEM cells were precultured with GM-CSF (GM), E21R (GM-CSR-R antagonist), or a combination of the two (comb.). The concentration of E21R (125 mg/ml) caused maximum antagonism as assessed by receptor binding studies (a). Bcl-2 levels were also measured (b). Pretreated CEM cells were then cultured with cisplatin for 3 days before assessing cell viability and percentage apoptosis (c). Data points in graphs represent the means and s.d.s of at least three separate experiments highest level of Epo-R compared to other solid tumours, which supported previous reports associating renal cancer with increased Epo serum levels and increased Epo-R expression (Da Silva et al., 1990) .
To verify whether ligand/receptor interactions were triggering intracellular signalling pathways, we next measured the extent of ERK di-phosphorylation by immunoblot techniques. The serine/threonine ERK is a MAPK that is activated in response to upstream cytokine receptors. Once dimerized, they proceed to autophosphorylate and associate with heterotrimeric G-proteins, activating downstream pathways (Lee and Mccubrey, 2002) . They play a crucial role in regulating cellular proliferation and survival (Boucher et al., 2000) , and are regulated by the kinase MEK (Matsuda et al., 1992; Seger et al., 1992) . It is important to stress that there are many MAPK pathways; however, the Ras/ Raf/MEK/ERK cascade is the most extensively studied (Lee and Mccubrey, 2002) , and is known to be directly activated in response to GF stimulation. Our results confirmed successful activation of these pathways, with the greatest activation seen in CEM, HL60 and K562 cells cultured with GM-CSF; parenthetically, these cells were highly expressive of GM-CSF-R. Similarly, the addition of Epo resulted in greatest activation in the K562 cell line that expressed the highest levels of Epo-R.
Epo and GM-CSF have been shown to be clastogenic agents, with the ability to increase the level of DNA damage within cells (Liu et al., 1998) . However, our results showed that culturing cells with GFs caused neither a cytotoxic nor a cytostatic response. Consequently, we went on to investigate the possibility that GFs had imparted a protective/survival advantage. It is important to emphasize that the intracellular signalling pathways by which GFs promote survival are only just being understood. Members of the MAPK pathway appear to play important roles in survival (Anderson, 1997; Ballif and Blenis, 2001 ) by promoting the expression of BCL-2 (Boucher et al., 2000) . Indeed, the in vitro modulation of the expression and phosphorylation of BCL-2 in leukaemic cells by haemopoietic GFs has been highlighted by a number of studies (Bradbury et al., 1994; Lotem and Sachs, 1995; Kapur and Zhang, 2001) . Our results confirmed the increase in BCL-2 expression in cells precultured with GFs, and showed levels to be increased only in those cells with the highest level of MAPK activation. The only exception to this was in the K562 cell line. Although K562 was highly expressive of Epo-R, and responded to the culture with Epo by inducing a high extent of MAPK activation, there was no upregulation of BCL-2. However, previous studies have shown that the cell line is severely p53/bcl-2-compromised (Bi et al., 1992) and expresses the protein at very low levels . Consequently, we measured BCL-xL, an antiapoptotic protein related to BCL-2 that is functional in K562 cells (Fukumi et al., 2000; Boucher et al., 2000) , and also found it to be unchanged after culture with both GFs (data not shown).
In all our cell lines, we could not demonstrate increased BCL-2 expression associated with culturing with Epo. Although the greatest MAPK activation was seen in the cell line with highest Epo-R, there was no increase in BCL-2 status. However, recent reports have detailed the key importance of functional p53 in determining MAPK-mediated cell kill induced by cisplatin (Park et al., 2001) , which would explain the observation in K562, which was null p53. Nevertheless, the two renal cancer cell lines expressing wild-type p53, ACHN and Caki 1, also demonstrated some MAPK activation following stimulation with Epo, but did not upregulate BCL-2. This apparent divergence of the GF-receptor/bcl-2 pathway suggested that (1) a more complex signalling pathway may be involved or (2) the requisite of exceeding a receptor activation-threshold for effect.
The overexpression of BCL-2 is known to render cells resistant to cisplatin-induced cell death (Park et al., 2001) . We therefore tested the sensitivity of cells precultured with CF to cisplatin, and found that cell lines which upregulated BCL-2 were less sensitive to cisplatin by about 30%. The role of MAPK in drug sensitivity was confirmed in two ways: firstly, through inhibiting the upstream regulator MEK with a specific inhibitor. We clearly showed that the inhibition of MAPK phosphorylation in GF-treated cells was associated with the ablation of BCL-2 upregulation, and a reversal of the GF-induced loss of sensitivity to cisplatin. Secondly, the transient transfection of constitutively active MEK cDNA into the HCT116 cell line resulted in a phenotype that expressed basal levels of pMAPK and BCL-2 that were much higher than that in the parental controls. The phenotype was also less sensitive to the cytotoxic effects of cisplatin. Conversely, the transfection of constitutively inactive MEK cDNA into the GM-CSF-responsive HL60 cell line resulted in the abrogation in the GF-induced upregulation of BCL-2 and the resulting cisplatin resistance.
Recent studies have shown that in addition to promoting the survival, proliferation and differentiation of immature erythroid cells through associations with the ERK pathway, Epo has been shown to modulate other MAPK and cellular signal transduction pathways (JNK and p38) (Silva et al., 1999; Kapur and Zhang, 2001; Chong et al., 2002) . Indeed, it has been suggested that the ERK MAPK pathway may not be the principal mechanism of Epo activity (Kolonics et al., 2001) . Consequently, the particular involvement of ERK, and its associated adverse effects of reducing drug sensitivity, may in fact be less of an issue in Epo-treated cells. This suggests the administration of Epo may be safe in renal cancers, which are associated with high Epo-R levels.
In summary, we have shown the central importance of receptor levels in regulating BCL-2 and the subsequent response to a cytotoxic chemotherapy. Specifically, although serum concentrations of these GFs and their receptor levels have been measured previously (de Jong et al., 1997; Pless et al., 1997; Gerharz et al., 2001; Hisakawa et al., 2001) , we believe that this is the first report to assess receptor levels with a unique nonradioactive method, and to correlate their levels with cellular function and phenotypic alterations. Our data also suggest distinct MAPK pathway activation following Epo-R or GM-CSF-R stimulation. Both Epo and GM-CSF increased kinase activity; however, use of GM-CSF in cells expressing a high level of GF-receptor level led to an increase in BCL-2, and decreased drug sensitivity. Conversely, in cells with moderately high Epo-R, basal BCL-2 expression following Epo treatment remained unchanged, and consequently these cells were insensitive to this detrimental GF effect.
In conclusion, these data highlight the potential detrimental effect of using GF and chemotherapy together in tumour types that express high levels of the relevant receptor.
Materials and methods
Cell culture
ACHN (renal adenocarcinoma), Caki-1 (renal carcinoma), CEM (acute lymphoblastic leukaemia), HCT116 (colorectal adenocarcinoma), HL60 (acute promyelocytic leukaemia), K562 (chronic myeloid leukaemia) and U266 (multiple myeloma) were obtained from the European Collection of Cell Cultures (Wiltshire, UK) and maintained in RPMI-1640 medium supplemented with 10% foetal bovine serum, apart from HCT116, which was cultured in DMEM. No antibiotics were used in any of our experiments, and all cell lines were incubated in a humidified atmosphere with 5% CO 2 in air at 371C.
To study the effect of GFs on cell growth, cells (2 Â 10 5 /ml) growing exponentially were reset in fresh culture medium supplemented with either Epo (Eprex, St Bartholomew's Hospital Pharmacy; 0-20 IU/ml) or GM-CSF (Leucomax, St Bartholomew's Hospital Pharmacy; 0-250 ng/ml) for 3 days. Cell number, cell viability, MAPK activation and BCL-2 expression were then assessed on day 3. The effects on cell parameters of inhibiting MAPK by culturing with the MEK inhibitor U0126 (Favata et al., 1998) , and inhibiting GM-CSF binding with the selective competitive antagonist E21R (Lopez et al., 1992) were investigated in CEM cells only. Cells (2 Â 10 5 / ml) were cultured with either U0126 (5 mM; Promega Ltd, Southampton, UK) or with E21R (125 mg/ml; BresaGen Ltd, Adelaide, Australia) in the presence or absence of GM-CSF (100 ng/ml). Cell parameters were then assessed on day 3.
Transfection with MEK constructs
This study involved the use of the following two expression plasmids that were gifts from Dr Natalie Ahn (University of Colorado, Boulder, CO, USA): human haemagglutinin-tagged constitutively active MEK cDNA (R4F mutant) and human haemagglutinin-tagged inactive MEK cDNA (8E(K97M)) (Mansour et al., 1994) . HL60 and HCT116 cells (4 Â 10 5 ) were plated into 24-well plates with 500 ml of culture medium, before addition of cDNA with LipofectAMINE solution according to the manufacturer's protocol (Invitrogen Ltd, Paisley, UK). The cDNA were added at a concentration of 500 ng/ml. At 4 h of incubation, culture medium was supplemented with phytohaemagglutinin-L (1 mg/ml; Sigma-Aldrich Company Ltd, Dorset, UK) and phorbol-12-myristate-13-acetate (50 ng/ml; Sigma). Cells were incubated for a further 2 days before assessment of transfection success/efficiency by flow cytometric analyses of HA tag using the HA-tag-FITC antibody according to the manufacturer's instructions (1 : 800; Abcam Ltd, Cambridge, UK). Successfully transformed cells were then subjected to the tests as described above.
DNA analysis
The distinct phases of the cell cycle were distinguished by flow cytometry, according to methods described previously (Liu et al., 2002a) . Acquisition of data was performed within 1 h using a FACSCalibur (BD Biosciences, Oxford, UK). In all, 5000 cells were analysed for each data point, and the percentages of cells in sub-G1 (apoptotic fraction -cells with a reduced DNA content but similar morphology), G1, S and G2/M phases were determined using the cell cycle analysis program CELLQuest v3.4 (BD Biosciences).
Flow cytometric analysis of BrdU incorporation
The degree of incorporation of the thymidine analogue 5-bromo-2 0 -deoxyuridine (BrdU) in cells was measured by flow cytometry. Following culture in Epo and GM-CSF, cells (5 Â 10 5 cells/ml) were transferred into fresh culture medium containing 10 mM BrdU for 30 min before fixing with ice-cold 70% ethanol and permeabilization in 2 M HCl with 0.5% Triton X-100. Samples were washed and incubated with fluorescein isothiocyanate (FITC)-conjugated mouse antiBrdU according to the manufacturer's instructions (PharMingen, San Diego, CA, USA). The cell cycle distribution was resolved by staining with propidium iodide, and BrdU fluorescence specifically within the S phase was measured by using the FACSCalibur.
Immunoblotting analysis
Total cellular protein was solubilized and resolved by SDS-PAGE using 15% acrylamide with a 5% stacking gel as described previously (Liu et al., 2002a) . Primary antibody probing was performed with anti-activated-MAPK (p42 ERK1 and p44
ERK2
; 1 : 2000; Sigma). Anti-b-actin was used as a loading control (1 : 2000; Oncogene Research Products, Boston, MA, USA). Following a washing step in 0.1% Tween in tris buffered saline (100 mM Tris, 150 mM NaCl, pH 7.6), horseradish peroxidase-conjugated anti-species IgG1 was used as the secondary antibody (DAKO Ltd, Cambridge, UK). Bands were visualized by the ECL plus detection system (Amersham Biosciences Ltd, Little Chalfont, UK).
Biotinylation of growth factors and determination of growth factor receptor levels
GFs were irreversibly biotinylated with biotin-XX-NHS (CN Biosciences Ltd, Nottingham, UK) according to the manufacturer's instructions with slight modifications (McGuckin et al., 1995) . The N-hydroxysuccinimide (NHS) spacer ester was employed to reduce steric hindrance associated with streptavidin and biotin binding. Stock concentrations of Epo (10 000 IU/ml) and GM-CSF (100 mg/ml) were incubated with biotin-XX-NHS (2 mg/ml) at a ratio of 1 : 3 for 6 h at room temperature. Phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin was added to remove/dilute excess biotin, and GFs were then centrifuged in a Microcon YM-100 centrifugal filter unit (Millipore Ltd, Watford, UK). The residue (biotinylated GF) was then collected from the filter head by reverse centrifugation, and made up to a volume of 100 ml with 0.1% BSA in PBS (Solution A).
Cells (1 Â 10 6 ) were resuspended in 100 ml of PBS, and incubated with 10 ml of biotinylated Epo or GM-CSF for 1 h. Following three washing steps in Solution A, cells were incubated with streptavidin-FITC conjugate (1 : 100; CN Biosciences) for 45 min at 41C. Cells were washed thrice, and resuspended in 500 ml of PBS for flow cytometric analysis using the FACSCalibur. In all, 5000 events were recorded and the mean FITC fluorescence in each sample was measured and assessed using dedicated software (CellQuest).
Assessment of BCL-2 protein levels by flow cytometry
Cells (1 Â 10 6 ) were washed in ice-cold PBS, and then fixed in 1 ml of 0.25%. paraformaldehyde. Following an incubation period of 15 min at room temperature, cells were washed and incubated in 1 ml of ice-cold 70% methanol at 41C for 30 min. Cells were then washed in ice-cold PBS and incubated with 10 ml of FITC-conjugated anti-BCL-2 (DAKO) at 41C for 30 min. FITC-conjugated mouse anti-IgG1 was used as the isotype control (DAKO). Finally, cells were washed in ice-cold PBS before staining with 500 ml of PI stain (50 mg/ml propidium iodide and 50 mg/ml RNAse A). Dual staining flow cytometric analysis was performed within 1 h using the FACSCalibur. A total of 5000 cells were analysed for BCL-2 fluorescence.
Effect of GF on cisplatin-induced cytotoxicity
The effect of a 3-day culture with the standard cytotoxic agent cisplatin was investigated in the cell lines. Cells were cultured with cisplatin (Sigma) at their respective IC 50 concentrations (the concentration required to induce approximately 50% cell kill). Cell number, viability and cell cycle dynamics were then assessed on day 3. Similarly, the cytotoxic effect of this 3-day culture with cisplatin was also investigated in the cells precultured for 3 days with 10 IU/ml Epo and 100 ng/ml GM-CSF. The GF concentrations selected were optimal concentrations as established previously (Liu et al., 2002b) . Cell parameters listed previously were then assessed on the final day (day 6). An additional experiment was performed with CEM cells precultured with GM-CSF and U0126 prior to assessment of cisplatin-induced cytotoxicity.
Statistical analysis
All statistical analyses were performed using Minitab version 10 (State College, PA, USA). Any differences between variables and control cultures, as determined by analysis of variance, were further characterized by paired analysis tests.
